Abstract:Background Chronic migraine is a common and highly disabling disorder. Functional MRI has indicated that abnormal brain region activation is linked with chronic migraine. Drugs targeting the calcitonin gene-related peptide (CGRP) or its receptor have been reported to be efficient for treating chronic migraine. The CGRP signaling was also shared in two types of chronic migraine models (CMMs). However, it remains unclear whether the activation of specific brain regions could contribute to persistent behavioral sensitization, and CGRP receptor antagonists relieve migraine-like pain in CMMs by altering specific brain region activation. Therefore, it’s of great interest to investigate brain activation pattern and the effect of olcegepant (a CGRP receptor-specific antagonist) treatment on alleviating hyperalgesia by altering brain activation in two CMMs, and provide a reference for future research on neural circuits. Methods Repeated administration of nitroglycerin (NTG) or levcromakalim (LEV) was conducted to stimulate human migraine-like pain and establish two types of CMMs in mice. Mechanical hypersensitivity was evaluated by using the von Frey filament test. Then, we evaluated the activation of different brain regions with c-Fos and NeuN staining. Olcegepant was administered to explore its effect on mechanical hyperalgesia and brain region activation. Results In two CMMs, acute and basal mechanical hyperalgesia was observed, and olcegepant alleviated mechanical hyperalgesia. In the NTG-induced CMM, the medial prefrontal cortex (mPFC), anterior cingulate cortex (ACC), and the caudal part of the spinal trigeminal nucleus (Sp5c) showed a significant increase of c-Fos expression in the NTG group ( p < 0.05), while pre-treatment with olcegepant reduced c-Fos expression compared with NTG group ( p < 0.05). No significant difference of c-Fos expression was found in the paraventricular thalamic nucleus (PVT) and ventrolateral periaqueductal gray (vlPAG) between the vehicle control and NTG group ( p > 0.05). In the LEV-induced CMM, mPFC, PVT, and Sp5c showed a significant increase of c-Fos expression between vehicle control and LEV group, and olcegepant reduced c-Fos expression ( p < 0.05). No significant difference in c-Fos expression was found in vlPAG and ACC ( p > 0.05). Conclusions Our study demonstrated the activation of mPFC and Sp5c in two CMMs. Olcegepant may alleviate hyperalgesia of the hind paw and periorbital area by attenuating brain activation in CMMs.

Neuroanatomical evidence and a mouse calcitonin gene-related peptide model in line with human functional magnetic resonance imaging data support the involvement of peptidergic Edinger-Westphal nucleus in migraine

Peripheral CGRP engages brain-wide electrical network activity of migraine

Antagonism of CGRP Receptor: Central and Peripheral Mechanisms and Mediators in an Animal Model of Chronic Migraine

Stimulation of CGRP-expressing neurons in the medial cerebellar nucleus induces light and touch sensitivity in mice

Peripherally administered calcitonin gene–related peptide induces spontaneous pain in mice: implications for migraine

A c-Fos activation map in NTG/levcromakalim-induced chronic migraine mice

The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine

Dynamic changes in CGRP, PACAP, and PACAP receptors in the trigeminovascular system of a novel repetitive electrical stimulation rat model: Relevant to migraine

CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine

Calcitonin Gene-Related Peptide Receptor Positive Neurons In Central Amygdala Modulate Pain In Mice

A C-Fos Activation Map in Nitroglycerin/levcromakalim-Induced Models of Migraine

Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine-like pain

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond

Detecting Abnormal Neuronal Activity in a Chronic Migraine Model by Egr1-EGFP Transgenic Mice

Systemic Calcitonin Gene-Related Peptide (CGRP) modifies auditory and vestibular endorgan electrical potentials, and increases auditory and vestibular hypersensitivities

Systemic Calcitonin Gene-Related Peptide (CGRP) modifies auditory and vestibular end organ electrical potentials, and increases sensory hypersensitivities

CGRP receptors in the control of pain and inflammation

Schwann cell endosome CGRP signals elicit periorbital mechanical allodynia in mice

Molecular studies of CGRP and the CGRP family of peptides in the central nervous system

Neuropeptide FF receptor 2 inhibits capsaicin-induced CGRP Upregulation in mouse trigeminal ganglion

Delta opioid receptor regulation of CGRP dynamics in the trigeminal complex